Overview

A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of sintilimab and chidamide in combination with or without IBI305 in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University